ClinicalTrials.gg
CompletedNCT04013581Updated May 4, 2021

Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen

A Phase 4 interventional study of TZD group and SGLT-2 group in Type 2 Diabetes Mellitus, sponsored by Yonsei University. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-05-04.

Sponsored by Yonsei University · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
19 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Diabetes Mellitus, Type 2 by Yonsei University — 5 open to participants now, 6 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Yonsei University.

Enrollment
2nd of 13
121 · median 61
Started
2019
the only one that year
Phase 4
10 of 20
3 open now
Registered
14th of 20
by date

Among the 20 studies in Diabetes Mellitus, Type 2 by Yonsei University, this one is the 2nd largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2019, is one of 10 in phase 4, and was the 14th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

5 of the 20 studies in Diabetes Mellitus, Type 2 by Yonsei University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 19 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Diabetes Mellitus, Type 2 by Yonsei University, or all of them as a file.
02

Study summary

In the treatment of type 2 diabetes (T2D), the number of patients requiring combination therapy of oral antidiabetic agents (OADs) is more than 70%. Especially in Korea, the tendency to avoid insulin therapy is relatively higher than other countries, therefore, the need for combination therapy of OADs is quite high. However, according to the current guidelines, clinicians are recommended to prescribe three or fewer OADs as the combination therapy for T2D. Recently, various OADs have been developed, and it is expected that quadruple combination therapy of OADs would be quite effective to lower blood glucose levels. In the present study, the investigators designed the study to compare the efficacy and safety of quadruple combination therapy; thiazolidinedione (TZD) vs. SGLT-2 inhibitor as an add-on therapy to triple combination therapy (Metformin, Sulfonylurea, Dipeptidyl peptidase-4(DPP-4) inhibitors). Quadruple combination therapy group with the SGLT-2 inhibitor will be considered as active control group, because it have shown non-inferior glycemic efficacy to the conventional insulin conversion therapy in a previous clinical study. Patients who could not achieve the target blood glucose level (7% \<HbA1c ≤ 10%) under the triple combination therapy (Metformin, Sulfonylurea, DPP-4 inhibitors) for more than 12 weeks will be enrolled in this prospective, open-label, randomized, parallel comparison, multicenter clinical trial. Subjects in each group (60 patients/group) will be treated with TZD-containing quadruple therapy or SGLT-2 inhibitor-containing quadruple therapy for 24 weeks. The investigators will evaluate the glycemic efficacy and safety of each group. Primary outcome is the 24 week-change of HbA1c from baseline levels.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. 19 ≤ age ≤ 80, male or female
    1. Type 2 diabetes patients who have taken triple combination therapy of OADs as followed : Metformin (≥1000 mg/day), Sulfonylurea (Glimepiride ≥ 4 mg/day or Gliclazide ≥ 60 mg/day), DPP-4 inhibitor (Full dose) for over 12 weeks
    1. At screening, 7% \< ≤ 10%
    1. Patients who refused insulin therapy.
    1. Subjects who understood the contents of the clinical trial and are cooperative in the trial progress, and are considered to be able to participate until the end of the trial.
    1. Patients who have voluntarily agreed in writing to participate in the clinical trial after hearing the explanation of the trial.

Exclusion criteria

Exclusion Criteria:

    1. Type 1 diabetes, gestational diabetes, and other types of diabetes than type 2 diabetes mellitus.
    1. Patients who have the history of allergy of for the medication of the clinical trial.
    1. Patients who have the history of taking TZDs or SGLT-2 inhibitors within a year prior to screening visit, or have the history of discontinuation of them due to severe side effects.
    1. Patients who have the history of acute or chronic metabolic acidosis including diabetic ketoacidosis (with or without coma), or any kinds of ketosis within 12 weeks prior to screening visit.
    1. Patients who have genetic metabolic diseases, such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
    1. Patients who have the history of taking for more than 2 weeks, within 8 weeks prior to screening visit.
    1. Patients who have the history of within 5 years prior to screening visit (In case of bladder cancer, subjects will be excluded regardless of the time of diagnosis)
    1. Patients who have the history of coronary artery bypass surgery or percutaneous coronary intervention, or suffered from heart failure ( class III, IV)
    1. Patients who have the history of uncontrolled arrhythmia, unstable angina, myocardial infarction, stroke, , and cerebral vascular disease within 24 weeks prior to the screening date.
    1. Patients of chronic renal failure, chronic kidney disease stage 3\~5 (estimated calculated vial CKD-EPI \<60 mL/min/1.73m2) or on dialysis therapy.
    1. Elevated liver enzymes (, ALT, ALP ≥ 2.5* (ULN) or Total ≥ 2.5*ULN) or class B or C (for the patients of liver cirrhosis)
    1. Subjects who are pregnant or lactating
    1. Perioperative patients, patients with severe infections or severe trauma
    1. Patients with unexamined gross hematuria
    1. Any other subjects who is determined to be ineligible for the clinical trials by researchers.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
121 participants (actual)

Study arms

  • Experimental
    TZD group

    Pioglitazone added to Metformin, DPP-4 inhibitors, Sulfonylurea

    Drug: TZD group

  • Active comparator
    SGLT-2 inhibitor group

    Empagliflozin added to Metformin, DPP-4 inhibitors, Sulfonylurea

    Drug: SGLT-2 group

Interventions

  • DrugTZD group

    Pioglitazone 15mg (Acpio®, once daily, regardless of meal time, for 24 weeks) will be added for T2DM(type 2 diabetes mellitus) patients who had inadequate glycemic control (7% \<HbA1c ≤ 10%) with triple therapy (metformin, DPP-4 inhibitors, sulfonylurea). At visit 3 (after 12 week-treatment), patients whose HbA1c level is more than 7.0% will be prescribed increased dosage of pioglitazone : from 15mg to 30mg

    Also known as: Acpio

  • DrugSodium/Glucose Cotransporter 2Studies of Sodium/Glucose Cotransporter 2Sodium/Glucose Cotransporter 2 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Empagliflozin 10mg (Jardiance®, once daily, regardless of meal time, for 24 weeks) will be added for T2DM patients who had inadequate glycemic control (7% \<HbA1c ≤ 10%) with triple therapy (metformin, DPP-4 inhibitors, sulfonylurea). At visit 3 (after 12 week-treatment), patients whose HbA1c level is more than 7.0% will be prescribed increased dosage of empagliflozin : from 10mg to 25mg

    Also known as: Jardiance

06

What researchers measure

Primary outcomes

  1. Change of HbA1c

    Time frame: 12 weeks

  2. Change of HbA1c

    Mean difference of HbA1c after 24 week-treatment

    Time frame: 24 weeks

Secondary outcomes

  1. glucose

    Percentage of patients who achieve target HbA1c (≤7% level)

    Time frame: 12 weeks

  2. glucose

    Mean difference of fasting blood glucose after 24 week-treatment

    Time frame: 24 weeks

  3. Adverse events

    Incidence of adverse events during treatment period

    Time frame: 12 weeks

  4. Adverse events

    Incidence of adverse events during treatment period

    Time frame: 24 weeks

  5. Change of kidney function

    Mean change of BUN and serum creatinine

    Time frame: 12 weeks

  6. Change of kidney function

    Mean change of BUN and serum creatinine

    Time frame: 24 weeks

  7. Change of liver enzymes

    Mean change of AST(Asparate aminotransferase)

    Time frame: 12 weeks

  8. Change of liver enzymes

    Mean change of ALT(Alanine aminotransferase)

    Time frame: 12 weeks

  9. Change of liver enzymes

    Mean change of Total bilirubin

    Time frame: 12 weeks

  10. Change of liver enzymes

    Mean change of AST

    Time frame: 24 weeks

  11. Change of liver enzymes

    Mean change of ALT

    Time frame: 24 weeks

  12. Change of liver enzymes

    Mean change of Total bilirubin

    Time frame: 24 weeks

07

Study locations

1 site
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in May 2020, 9 months.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's 9 months is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2019
First posted
Jul 9, 2019
StartActual
Aug 5, 2019
Primary completionActual
May 13, 2020
CompletionActual
May 28, 2020
Last update
May 4, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04013581
Lead sponsor
Yonsei University
Responsible party
Sponsor
First posted
Jul 9, 2019
Start date
Aug 5, 2019
Primary completion
May 13, 2020
Completion
May 28, 2020
Last update
May 4, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion